The Board of Directors has appointed Andrew A. Lukowiak to serve as President and Chief Scientific Officer of Talis Biomedical Corporation (the "Company"), effective August 1, 2023 (the "CSO Start Date"). Prior to joining the Company, Dr. Lukowiak, 51, was the President, Chief Scientific Officer and board member of Epigenomics AG, a publicly traded molecular diagnostics company that developed the first FDA approved, blood based, colorectal, cancer screening test. From 2018 to 2021, Dr. Lukowiak was the Chief Executive Officer and board member of Millenium Health, a privately held clinical laboratory improvement amendments ("CLIA") laboratory specializing in clinical toxicology services.

Prior to Millenium Health, Dr. Lukowiak was the Chief Operating Officer and Chief Executive Officer for Althea Dx, a private equity-backed CLIA laboratory providing proprietary, clinically-validated pharmacogenetic testing services from 2013 to 2018. Dr. Lukowiak earned Bachelor of Science in Biology from the Pennsylvania State University and a Ph.D. in Genetics from the University of Georgia.